Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

Eisai sepsis drug fails in phase III

January 26, 2011 Research and Development, Sales and Marketing Eisai, eritoran, perampanel, sepsis

A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …
News
Amgen HQ

Amgen signs $1 billion cancer biotech deal

January 25, 2011 Research and Development Amgen, BioVex, OncoVEXGM-CSF, cancer vaccine

Amgen is set to pay $1 billion for US biotech firm BioVex, in the process gaining access to its novel …
News
GlaxoSmitKline's headquarters

GSK skin cancer drugs moves into phase III

January 25, 2011 Research and Development BRAF V600 mutation, Cancer, Duchenne Muscular Dystrophy, GSK, GSK1120212, GSK2118436, GSK968, GlaxoSmithKline, melanoma, skin cancer

GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …
News

Novartis offers $470m to boost personalised cancer treatment

January 24, 2011 Research and Development, Sales and Marketing Cancer, Genoptix, Novartis, cancer diagnostics, personalised medicine

Novartis has offered $470 million for a California-based laboratory whose diagnostic services it hopes will enhance personalised treatment. Genoptix specialises …
News

Contract research news in brief

January 24, 2011 Research and Development AMRI, Applied Clinical Intelligence, Cenix Bioscience, Clinipace Worldwide, ICON, PPD, Pacific Biomarkers, monoclonal antibody

PPD sets up a monoclonal antibody JV in Singapore, plus updates from Icon plc, Cenix Bioscience, Clinipace Worldwide, Pacific Biomarkers, …
News

Penn Pharma appoints Wyeth’s Edward Rowland

January 20, 2011 Manufacturing and Production, Research and Development Edward Rowland, Penn Pharma, appointment, manufacturing and production, research and development

Edward Rowland has joined Wales-based pharmaceutical drug developer and manufacturer Penn Pharma as head of operational analytical services. He moves …
Appointment
Roche building

Trial success for Roche’s personalised skin cancer drug

January 19, 2011 Research and Development BRAF V600, Cancer, RG7204, Roche, personalised medicine, skin cancer

A promising Roche drug has helped previously untreated patients with advanced skin cancer to live longer without their disease getting …
News

EMA’s Thomas Lönngren joins market access firm

January 19, 2011 Research and Development, Sales and Marketing NDA Group, Thomas Lönngren, appointment, recruitment, research and development, sales and marketing

The former head of the EMA Thomas Lönngren has taken up a post at new European regulatory and market access …
News

Sanofi ‘considering’ raising Genzyme offer

January 19, 2011 Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi, Sanofi-Aventis, pharma mergers and acquisitions

Sanofi-Aventis could be willing to raise its offer to $76 a share to buy the US biotech firm Genzyme, according …
News

Success in pre-clinical microRNA treatment of prostate cancer

January 19, 2011 Research and Development MD Anderson Cancer Center, MicroRNA, Mirna Therapeutics, RNA interfering, miRNA, prostate cancer, rnai

A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …
News

Syntaxin appoints Russell Greig chairman

January 19, 2011 Research and Development Russell Greig, appointment, research and development, syntaxin

Oxford, UK-based biotechnology company Syntaxin has appointed Dr Russell Greig as its new chairman.Russell has over 30 years experience in …
Appointment

Chiltern wins multiple Pharma Awards at the prestigious annual Pharmatimes Awards Ceremony

January 18, 2011 Research and Development

 
News
Press release

Merck Serono and Domain to co-develop Parkinson’s drugs

January 18, 2011 Research and Development Domain Therapeutics, Merck KGaA, Merck Serono, PAM, Parkinson's disease, Parkinson’s disease, Positive Allosteric Modulator, mGluR4, metabotropic glutamate receptor 4

Merck Serono is to work with French biotech company Domain Therapeutics to develop a new treatment for Parkinson’s disease and …
News

Merck suffers late-stage blow to vorapaxar

January 18, 2011 Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar

An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …
News

Merck taps Parexel to help it meet biosimilar ambitions

January 18, 2011 Research and Development Merck & Co, Parexel, biosimilars

Merck & Co has enlisted the aid of contract research organisation Parexel to help it develop biosimilar versions of some …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026